{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:18:15Z","timestamp":1771989495052,"version":"3.50.1"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"4546","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>Biotechnological  advances now enable the design of fully human antibodies to target specific  antigens in a growing number of diseases. Monoclonal antibodies (mAbs) differ  from traditional small chemical molecules in several ways: (1) biological production  \u2012 they are grown in and extracted from cell cultures; (2) specificity \u2012 they  demonstrate high target specificity, with a low risk of drug-drug interactions;  (3) administration \u2012 they are delivered parenterally (intravenously or  subcutaneously); (4) dosage interval \u2012 their extended half-lives generally  allow for spaced dosing (from weekly to monthly). In cardiology, fully human  mAbs directed against proprotein convertase subtilisin \/ kexin type 9 (PCSK9) have   shown to be effective in reducing low-density lipoprotein cholesterol  (LDL-C) in phase II clinical trials among patients with familial  hypercholesterolaemia (FH). PCSK9 inhibitors have just received approval for the treatment of FH and clinical atherosclerotic disease, and patients not at target under maximally tolerated statin therapy or intolerant to statins. Large-scale phase III  trials are currently assessing the role of PCSK9 inhibitors in the secondary prevention setting for patients with acute  coronary syndromes (ACS) and poorly controlled LDL-C under evidence-based  therapies. Another area currently under investigation for  fully human mAbs  in secondary prevention is their potential ability to inhibit inflammatory  pathways. In this context, canakinumab, a specific mAb inhibiting interleukin-1\u03b2 (IL-1\u03b2), has already received approval for the treatment of systemic juvenile idiopathic arthritis. The  canakinumab anti-inflammatory thrombosis outcomes trial (CANTOS) is an ongoing  trial assessing whether inhibition of IL-1\u03b2 could reduce the occurrence of cardiovascular  adverse events in 17,200 patients with ACS and with defined persisting  inflammation.<\/jats:p>","DOI":"10.4414\/smw.2015.14179","type":"journal-article","created":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T10:03:57Z","timestamp":1454061837000},"page":"w14179","source":"Crossref","is-referenced-by-count":3,"title":["Use and  role of monoclonal antibodies and other biologics in\u00a0preventive cardiology"],"prefix":"10.57187","volume":"145","author":[{"given":"Baris","family":"Gencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reijo","family":"Laaksonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliki","family":"Buhayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2015,11,1]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/2094\/3066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/2094\/3067","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/2094\/3066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:40:22Z","timestamp":1755240022000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/2094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":0,"journal-issue":{"issue":"4546","published-online":{"date-parts":[[2015,11,2]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2015.14179","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}